Enanta Pharmaceuticals (ENTA) EBIAT: 2012-2025
Historic EBIAT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.7 million.
- Enanta Pharmaceuticals' EBIAT rose 35.12% to -$18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.9 million, marking a year-over-year increase of 29.43%. This contributed to the annual value of -$81.9 million for FY2025, which is 29.43% up from last year.
- Per Enanta Pharmaceuticals' latest filing, its EBIAT stood at -$18.7 million for Q3 2025, which was down 2.44% from -$18.3 million recorded in Q2 2025.
- Enanta Pharmaceuticals' 5-year EBIAT high stood at -$18.3 million for Q2 2025, and its period low was -$39.1 million during Q2 2023.
- Over the past 3 years, Enanta Pharmaceuticals' median EBIAT value was -$28.1 million (recorded in 2023), while the average stood at -$27.5 million.
- As far as peak fluctuations go, Enanta Pharmaceuticals' EBIAT tumbled by 267.11% in 2021, and later skyrocketed by 42.00% in 2024.
- Enanta Pharmaceuticals' EBIAT (Quarterly) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then declined by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then surged by 35.12% to -$18.7 million in 2025.
- Its last three reported values are -$18.7 million in Q3 2025, -$18.3 million for Q2 2025, and -$22.6 million during Q1 2025.